Dual 5-HT 2A and 5-HT 2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01244 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Takuya Oguma und 18 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Medicinal Chemistry Research, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Hauptthemen laut MEDLINE: Antipsychotic Agents, Receptor, Serotonin, 5-HT2A, Psychotic Disorders, Serotonin 5-HT2 Receptor Agonists. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Themen: Demenz
Abstract (Originalsprache)
Psychosis is a distressing symptom commonly occurring in people with dementia. To treat Parkinson's disease psychosis, pimavanserin (1), a 5-HT2A receptor inverse agonist having minimal 5-HT2C receptor affinity and no dopamine D2 receptor affinity, was approved in the United States, but not for dementia-related psychosis due to limited efficacy issues. Herein, we report on the identification of a potent and dual 5-HT2A and 5-HT2C receptor inverse agonist 8 having minimal hERG inhibition, after having demonstrated the involvement of both 5-HT2A and 5-HT2C receptors to deliver antipsychotic efficacy in an MK-801-induced locomotor model and having conducted 5-HT2A and 5-HT2C occupancy studies including a surrogate method. The introduction of a spirocyclopropyl group boosting 5-HT2C affinity in 1 followed by further optimization to control lipophilicity resulted in balanced dual potency and metabolic stability, and mitigating hERG inhibition led to 8 that showed significant antipsychotic efficacy due to the involvement of both receptors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory for Medicinal Chemistry Research, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
- Laboratory for Drug Discovery & Disease Research, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
- Department of Cell Biology, Graduate School of Medicine, Kyoto University, Sakyo-yu, Kyoto 606-8501, Japan.
- Laboratory for Bio-Modality Research, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
- Laboratory for Drug Discovery & Development, Shionogi Pharmaceutical Research Center, 1-1 Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan.
ORCID-Profile: Takuya Oguma, Ken-Ichi Kusakabe
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Oguma, T., Jino, K., Nakahara, K., Asada, H., Fuchino, K., Nagatani, K., Kouki, K., Okamoto, R., Takai, N., Koda, K., Fujita, S., Sekiguchi, Y., Yasuo, K., Mayumi, K., Abe, A., Imono, M., Horiguchi, N., Iwata, S., & Kusakabe, K. I. (2024). Dual 5-HT 2A and 5-HT 2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01244
Vancouver
Oguma T, Jino K, Nakahara K, Asada H, Fuchino K, Nagatani K, et al. Dual 5-HT 2A and 5-HT 2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01244
BibTeX
@article{Oguma2024,
author = {Oguma, Takuya and Jino, Kohei and Nakahara, Kenji and Asada, Hidetsugu and Fuchino, Kouki and Nagatani, Kotaro and Kouki, Kensuke and Okamoto, Ryuji and Takai, Nozomi and Koda, Ken and Fujita, Sayaka and Sekiguchi, Yusuke and Yasuo, Kazuya and Mayumi, Kei and Abe, Ayane and Imono, Masaaki and Horiguchi, Naotaka and Iwata, So and Kusakabe, Ken-Ichi},
title = {Dual 5-HT 2A and 5-HT 2C Receptor Inverse Agonist That Affords In Vivo Antipsychotic Efficacy with Minimal hERG Inhibition for the Treatment of Dementia-Related Psychosis},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01244}
}
EUVIMED